25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Scandinavian ChemoTech AB Series B
Buy, Hold or Sell?

Let's analyze Chemotech together

I guess you are interested in Scandinavian ChemoTech AB Series B. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Scandinavian ChemoTech AB Series B. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Scandinavian ChemoTech AB Series B

I send you an email if I find something interesting about Scandinavian ChemoTech AB Series B.

1. Quick Overview

1.1. Quick analysis of Chemotech (30 sec.)










1.2. What can you expect buying and holding a share of Chemotech? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.15
Expected worth in 1 year
kr-0.22
How sure are you?
27.3%

+ What do you gain per year?

Total Gains per Share
kr-0.37
Return On Investment
-21.0%

For what price can you sell your share?

Current Price per Share
kr1.75
Expected price per share
kr1.6350173651308 - kr2.48
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Chemotech (5 min.)




Live pricePrice per Share (EOD)
kr1.75
Intrinsic Value Per Share
kr-5.80 - kr-6.60
Total Value Per Share
kr-5.65 - kr-6.46

2.2. Growth of Chemotech (5 min.)




Is Chemotech growing?

Current yearPrevious yearGrowGrow %
How rich?$307.2k$987.2k-$325.1k-49.1%

How much money is Chemotech making?

Current yearPrevious yearGrowGrow %
Making money-$385k-$583.5k$198.5k51.6%
Net Profit Margin-479.2%-4,790.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Chemotech (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Chemotech?

Welcome investor! Chemotech's management wants to use your money to grow the business. In return you get a share of Chemotech.

First you should know what it really means to hold a share of Chemotech. And how you can make/lose money.

Speculation

The Price per Share of Chemotech is kr1.75. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Chemotech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Chemotech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.15. Based on the TTM, the Book Value Change Per Share is kr-0.09 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Chemotech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.02-0.9%-0.02-1.0%-0.02-1.4%-0.02-1.0%-0.01-0.8%
Usd Book Value Change Per Share-0.02-1.1%-0.01-0.5%0.00-0.1%0.00-0.2%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-1.1%-0.01-0.5%0.00-0.1%0.00-0.2%0.000.0%
Usd Price Per Share0.19-0.23-0.53-1.01-1.56-
Price to Earnings Ratio-2.99--3.28--5.59--15.63--40.52-
Price-to-Total Gains Ratio-9.61--6.18-69.87--21.31--112.55-
Price to Book Ratio14.47-8.77-12.47-18.66-25.18-
Price-to-Total Gains Ratio-9.61--6.18-69.87--21.31--112.55-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.158725
Number of shares6300
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (6300 shares)-52.55-18.33
Gains per Year (6300 shares)-210.20-73.31
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-210-2200-73-83
20-420-4300-147-156
30-631-6400-220-229
40-841-8500-293-302
50-1051-10600-367-375
60-1261-12700-440-448
70-1471-14800-513-521
80-1682-16900-586-594
90-1892-19000-660-667
100-2102-21100-733-740

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.033.00.00.0%0.033.00.00.0%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%9.021.03.027.3%9.021.03.027.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.033.00.0%0.00.033.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%6.014.00.030.0%9.021.03.027.3%9.021.03.027.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Scandinavian ChemoTech AB Series B compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.218-0.092-58%-0.024-89%-0.032-85%0.004-5070%
Book Value Per Share--0.1450.334-57%0.502-71%0.602-76%0.591-75%
Current Ratio--0.7191.138-37%1.193-40%2.992-76%3.407-79%
Debt To Asset Ratio--0.7780.536+45%0.460+69%0.364+113%0.283+175%
Debt To Equity Ratio--3.4961.594+119%0.905+286%0.790+342%0.723+384%
Dividend Per Share----0%-0%-0%-0%
Eps---0.176-0.192+9%-0.271+54%-0.202+15%-0.148-16%
Free Cash Flow Per Share---0.024-0.155+552%-0.242+922%-0.179+654%-0.124+425%
Free Cash Flow To Equity Per Share--0.009-0.019+303%0.020-53%0.008+15%0.021-56%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---6.603--------
Intrinsic Value_10Y_min---5.796--------
Intrinsic Value_1Y_max---0.838--------
Intrinsic Value_1Y_min---0.823--------
Intrinsic Value_3Y_max---2.383--------
Intrinsic Value_3Y_min---2.278--------
Intrinsic Value_5Y_max---3.766--------
Intrinsic Value_5Y_min---3.507--------
Market Cap37961525.000-29%49022353.80054980200.223-11%127326751.003-61%242600605.608-80%373141805.268-87%
Net Profit Margin---2.441-4.792+96%-47.903+1862%-148.116+5967%-97.896+3910%
Operating Margin---2.225-4.620+108%-40.654+1727%-142.827+6320%-94.932+4167%
Operating Ratio--6.10010.576-42%76.449-92%166.785-96%107.841-94%
Pb Ratio12.061-20%14.4748.770+65%12.471+16%18.656-22%25.180-43%
Pe Ratio-2.489+17%-2.986-3.275+10%-5.590+87%-15.632+423%-40.519+1257%
Price Per Share1.750-20%2.1002.495-16%5.870-64%11.176-81%17.197-88%
Price To Free Cash Flow Ratio-18.468+17%-22.162-8.114-63%-6.159-72%-0.050-100%-3249.016+14560%
Price To Total Gains Ratio-8.009+17%-9.611-6.182-36%69.872-114%-21.306+122%-112.550+1071%
Quick Ratio--0.4070.581-30%0.837-51%2.357-83%2.927-86%
Return On Assets---0.270-0.270+0%-0.322+20%-0.236-13%-0.171-36%
Return On Equity---1.212-0.685-43%-0.623-49%-0.437-64%-0.879-27%
Total Gains Per Share---0.218-0.092-58%-0.024-89%-0.032-85%0.004-5070%
Usd Book Value--307200.900662087.325-54%987269.500-69%1185449.000-74%1163606.359-74%
Usd Book Value Change Per Share---0.020-0.008-58%-0.002-89%-0.003-85%0.000-5070%
Usd Book Value Per Share--0.0130.030-57%0.046-71%0.055-76%0.054-75%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.016-0.017+9%-0.025+54%-0.018+15%-0.013-16%
Usd Free Cash Flow---50157.100-305001.425+508%-476288.375+850%-351408.080+601%-244914.247+388%
Usd Free Cash Flow Per Share---0.002-0.014+552%-0.022+922%-0.016+654%-0.011+425%
Usd Free Cash Flow To Equity Per Share--0.001-0.002+303%0.002-53%0.001+15%0.002-56%
Usd Market Cap3443110.318-29%4446327.4904986704.160-11%11548536.316-61%22003874.929-80%33843961.738-87%
Usd Price Per Share0.159-20%0.1900.226-16%0.532-64%1.014-81%1.560-88%
Usd Profit---372232.800-385044.175+3%-583563.800+57%-414385.625+11%-301388.500-19%
Usd Revenue--152466.700104599.775+46%35849.175+325%32316.410+372%28405.280+437%
Usd Total Gains Per Share---0.020-0.008-58%-0.002-89%-0.003-85%0.000-5070%
 EOD+3 -5MRQTTM+15 -18YOY+13 -205Y+16 -1710Y+10 -23

3.3 Fundamental Score

Let's check the fundamental score of Scandinavian ChemoTech AB Series B based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.489
Price to Book Ratio (EOD)Between0-112.061
Net Profit Margin (MRQ)Greater than0-2.441
Operating Margin (MRQ)Greater than0-2.225
Quick Ratio (MRQ)Greater than10.407
Current Ratio (MRQ)Greater than10.719
Debt to Asset Ratio (MRQ)Less than10.778
Debt to Equity Ratio (MRQ)Less than13.496
Return on Equity (MRQ)Greater than0.15-1.212
Return on Assets (MRQ)Greater than0.05-0.270
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Scandinavian ChemoTech AB Series B based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.979
Ma 20Greater thanMa 501.813
Ma 50Greater thanMa 1001.978
Ma 100Greater thanMa 2001.994
OpenGreater thanClose1.730
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Scandinavian ChemoTech AB Series B

Scandinavian ChemoTech AB (publ) offers cancer care and pain management solutions in Sweden. The company offers IQWave, an electroporation device, used for electrochemotherapy and treatment of head and neck cancer, squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, kaposi sarcoma, and transitional cell carcinoma. It also offers Vetiqure for the treatment of superficial tumors in dogs, cats, and horses. The company markets its products through distribution channels and a network of human medicine opinion leaders in the Middle East, Asia, India, and Africa. Scandinavian ChemoTech AB (publ) was incorporated in 2013 and is headquartered in Lund, Sweden.

Fundamental data was last updated by Penke on 2024-11-14 17:37:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Chemotech earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Chemotech to the Biotechnology industry mean.
  • A Net Profit Margin of -244.1% means that kr-2.44 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is -244.1%. The company is making a huge loss. -2
  • The TTM is -479.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-244.1%TTM-479.2%+235.0%
TTM-479.2%YOY-4,790.3%+4,311.1%
TTM-479.2%5Y-14,811.6%+14,332.5%
5Y-14,811.6%10Y-9,789.6%-5,022.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-244.1%-120.2%-123.9%
TTM-479.2%-210.7%-268.5%
YOY-4,790.3%-219.8%-4,570.5%
5Y-14,811.6%-348.0%-14,463.6%
10Y-9,789.6%-473.2%-9,316.4%
4.3.1.2. Return on Assets

Shows how efficient Chemotech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Chemotech to the Biotechnology industry mean.
  • -27.0% Return on Assets means that Chemotech generated kr-0.27 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is -27.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -27.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-27.0%TTM-27.0%+0.0%
TTM-27.0%YOY-32.2%+5.3%
TTM-27.0%5Y-23.6%-3.4%
5Y-23.6%10Y-17.1%-6.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.0%-11.0%-16.0%
TTM-27.0%-11.8%-15.2%
YOY-32.2%-11.3%-20.9%
5Y-23.6%-12.6%-11.0%
10Y-17.1%-14.3%-2.8%
4.3.1.3. Return on Equity

Shows how efficient Chemotech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Chemotech to the Biotechnology industry mean.
  • -121.2% Return on Equity means Chemotech generated kr-1.21 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is -121.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -68.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-121.2%TTM-68.5%-52.6%
TTM-68.5%YOY-62.3%-6.2%
TTM-68.5%5Y-43.7%-24.8%
5Y-43.7%10Y-87.9%+44.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-121.2%-14.1%-107.1%
TTM-68.5%-15.8%-52.7%
YOY-62.3%-13.9%-48.4%
5Y-43.7%-18.5%-25.2%
10Y-87.9%-19.2%-68.7%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Scandinavian ChemoTech AB Series B.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Chemotech is operating .

  • Measures how much profit Chemotech makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Chemotech to the Biotechnology industry mean.
  • An Operating Margin of -222.5% means the company generated kr-2.22  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is -222.5%. The company is operating very inefficient. -2
  • The TTM is -462.0%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-222.5%TTM-462.0%+239.5%
TTM-462.0%YOY-4,065.4%+3,603.4%
TTM-462.0%5Y-14,282.7%+13,820.7%
5Y-14,282.7%10Y-9,493.2%-4,789.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-222.5%-267.8%+45.3%
TTM-462.0%-313.4%-148.6%
YOY-4,065.4%-224.0%-3,841.4%
5Y-14,282.7%-385.5%-13,897.2%
10Y-9,493.2%-498.7%-8,994.5%
4.3.2.2. Operating Ratio

Measures how efficient Chemotech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 6.10 means that the operating costs are kr6.10 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is 6.100. The company is inefficient in keeping operating costs low. -1
  • The TTM is 10.576. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.100TTM10.576-4.476
TTM10.576YOY76.449-65.873
TTM10.5765Y166.785-156.209
5Y166.78510Y107.841+58.944
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1002.631+3.469
TTM10.5763.412+7.164
YOY76.4493.299+73.150
5Y166.7854.788+161.997
10Y107.8416.538+101.303
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Scandinavian ChemoTech AB Series B.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Chemotech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.72 means the company has kr0.72 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is 0.719. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.138. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.719TTM1.138-0.419
TTM1.138YOY1.193-0.055
TTM1.1385Y2.992-1.855
5Y2.99210Y3.407-0.414
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7193.690-2.971
TTM1.1383.875-2.737
YOY1.1934.684-3.491
5Y2.9925.946-2.954
10Y3.4076.274-2.867
4.4.3.2. Quick Ratio

Measures if Chemotech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Chemotech to the Biotechnology industry mean.
  • A Quick Ratio of 0.41 means the company can pay off kr0.41 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is 0.407. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.581. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.407TTM0.581-0.174
TTM0.581YOY0.837-0.256
TTM0.5815Y2.357-1.775
5Y2.35710Y2.927-0.570
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4073.122-2.715
TTM0.5813.451-2.870
YOY0.8374.498-3.661
5Y2.3575.922-3.565
10Y2.9276.414-3.487
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Scandinavian ChemoTech AB Series B.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Chemotech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Chemotech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.78 means that Chemotech assets are financed with 77.8% credit (debt) and the remaining percentage (100% - 77.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is 0.778. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.536. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.778TTM0.536+0.241
TTM0.536YOY0.460+0.077
TTM0.5365Y0.364+0.172
5Y0.36410Y0.283+0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7780.353+0.425
TTM0.5360.350+0.186
YOY0.4600.311+0.149
5Y0.3640.367-0.003
10Y0.2830.382-0.099
4.5.4.2. Debt to Equity Ratio

Measures if Chemotech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Chemotech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 349.6% means that company has kr3.50 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Scandinavian ChemoTech AB Series B:

  • The MRQ is 3.496. The company is unable to pay all its debts with equity. -1
  • The TTM is 1.594. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ3.496TTM1.594+1.902
TTM1.594YOY0.905+0.689
TTM1.5945Y0.790+0.804
5Y0.79010Y0.723+0.067
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.4960.393+3.103
TTM1.5940.435+1.159
YOY0.9050.378+0.527
5Y0.7900.451+0.339
10Y0.7230.493+0.230
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Chemotech generates.

  • Above 15 is considered overpriced but always compare Chemotech to the Biotechnology industry mean.
  • A PE ratio of -2.99 means the investor is paying kr-2.99 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Scandinavian ChemoTech AB Series B:

  • The EOD is -2.489. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.986. Based on the earnings, the company is expensive. -2
  • The TTM is -3.275. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.489MRQ-2.986+0.498
MRQ-2.986TTM-3.275+0.289
TTM-3.275YOY-5.590+2.315
TTM-3.2755Y-15.632+12.357
5Y-15.63210Y-40.519+24.887
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.489-2.126-0.363
MRQ-2.986-2.454-0.532
TTM-3.275-3.147-0.128
YOY-5.590-3.335-2.255
5Y-15.632-6.070-9.562
10Y-40.519-6.597-33.922
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Scandinavian ChemoTech AB Series B:

  • The EOD is -18.468. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.162. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.114. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-18.468MRQ-22.162+3.694
MRQ-22.162TTM-8.114-14.048
TTM-8.114YOY-6.159-1.955
TTM-8.1145Y-0.050-8.063
5Y-0.05010Y-3,249.016+3,248.966
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-18.468-2.981-15.487
MRQ-22.162-3.363-18.799
TTM-8.114-3.667-4.447
YOY-6.159-4.535-1.624
5Y-0.050-8.343+8.293
10Y-3,249.016-9.276-3,239.740
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Chemotech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 14.47 means the investor is paying kr14.47 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Scandinavian ChemoTech AB Series B:

  • The EOD is 12.061. Based on the equity, the company is expensive. -2
  • The MRQ is 14.474. Based on the equity, the company is expensive. -2
  • The TTM is 8.770. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD12.061MRQ14.474-2.412
MRQ14.474TTM8.770+5.703
TTM8.770YOY12.471-3.701
TTM8.7705Y18.656-9.886
5Y18.65610Y25.180-6.524
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD12.0611.863+10.198
MRQ14.4742.028+12.446
TTM8.7702.339+6.431
YOY12.4712.391+10.080
5Y18.6563.666+14.990
10Y25.1804.360+20.820
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets14,751
Total Liabilities5,786
Total Stockholder Equity8,965
 As reported
Total Liabilities 5,786
Total Stockholder Equity+ 8,965
Total Assets = 14,751

Assets

Total Assets14,751
Total Current Assets8,536
Long-term Assets6,215
Total Current Assets
Cash And Cash Equivalents 1,577
Net Receivables 3,426
Inventory 3,533
Total Current Assets  (as reported)8,536
Total Current Assets  (calculated)8,536
+/-0
Long-term Assets
Property Plant Equipment 4
Intangible Assets 6,000
Long-term Assets  (as reported)6,215
Long-term Assets  (calculated)6,004
+/- 211

Liabilities & Shareholders' Equity

Total Current Liabilities5,786
Long-term Liabilities-
Total Stockholder Equity8,965
Total Current Liabilities
Other Current Liabilities 5,786
Total Current Liabilities  (as reported)5,786
Total Current Liabilities  (calculated)5,786
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Other Stockholders Equity 8,965
Total Stockholder Equity (as reported)8,965
Total Stockholder Equity (calculated)8,965
+/-0
Other
Cash and Short Term Investments 1,577
Common Stock Shares Outstanding 23,344
Liabilities and Stockholders Equity 14,751
Net Debt -1,577



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-30
> Total Assets 
0
0
0
6,653
0
23,654
19,190
16,827
14,642
10,772
28,440
23,384
22,808
20,851
19,875
21,615
17,489
16,854
22,591
19,419
15,991
21,258
19,880
31,190
25,810
20,624
19,202
18,646
21,701
19,147
20,490
17,079
14,869
16,210
15,228
14,751
14,75115,22816,21014,86917,07920,49019,14721,70118,64619,20220,62425,81031,19019,88021,25815,99119,41922,59116,85417,48921,61519,87520,85122,80823,38428,44010,77214,64216,82719,19023,65406,653000
   > Total Current Assets 
12
0
0
3,606
0
19,503
14,807
12,146
8,752
1,935
18,031
11,122
8,295
10,627
8,598
9,960
5,530
4,568
10,378
7,292
4,131
8,865
6,557
18,317
13,436
8,940
8,145
8,173
11,818
9,944
12,187
8,900
7,198
9,006
8,510
8,536
8,5368,5109,0067,1988,90012,1879,94411,8188,1738,1458,94013,43618,3176,5578,8654,1317,29210,3784,5685,5309,9608,59810,6278,29511,12218,0311,9358,75212,14614,80719,50303,6060012
       Cash And Cash Equivalents 
-12
0
0
3,325
0
18,532
14,409
11,471
8,160
1,528
16,977
10,154
6,762
7,279
5,625
6,823
2,862
1,906
7,755
4,541
1,485
5,811
3,504
15,011
8,682
3,699
2,234
1,580
5,852
4,041
4,113
1,160
923
1,655
1,859
1,577
1,5771,8591,6559231,1604,1134,0415,8521,5802,2343,6998,68215,0113,5045,8111,4854,5417,7551,9062,8626,8235,6257,2796,76210,15416,9771,5288,16011,47114,40918,53203,32500-12
       Short-term Investments 
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000024
       Net Receivables 
0
0
0
14
0
0
0
0
566
369
0
0
587
2,698
2,315
2,381
674
1,758
1,703
1,692
665
1,683
1,718
1,907
1,531
2,464
2,867
3,276
2,870
2,722
4,921
3,895
2,241
3,310
2,966
3,426
3,4262,9663,3102,2413,8954,9212,7222,8703,2762,8672,4641,5311,9071,7181,6836651,6921,7031,7586742,3812,3152,69858700369566000014000
       Other Current Assets 
0
0
0
281
0
917
387
637
0
0
927
626
928
2,698
2,315
2,381
1,905
1,758
1,703
1,692
1,354
1,683
1,718
1,907
1,854
2,464
2,867
3,276
2,007
0
0
0
0
3,310
2,966
0
02,9663,31000002,0073,2762,8672,4641,8541,9071,7181,6831,3541,6921,7031,7581,9052,3812,3152,698928626927006373879170281000
   > Long-term Assets 
-12
0
0
3,047
0
4,151
4,383
4,681
5,891
8,838
10,408
12,262
14,512
10,224
11,277
11,655
11,959
12,286
12,213
12,127
11,860
12,393
13,323
12,873
12,374
11,684
11,057
10,473
9,883
9,203
8,303
8,179
7,671
7,204
6,718
6,215
6,2156,7187,2047,6718,1798,3039,2039,88310,47311,05711,68412,37412,87313,32312,39311,86012,12712,21312,28611,95911,65511,27710,22414,51212,26210,4088,8385,8914,6814,3834,15103,04700-12
       Property Plant Equipment 
0
0
0
0
0
0
0
129
0
117
105
93
71
67
58
71
87
70
55
40
62
89
77
84
73
62
53
42
35
27
22
17
12
8
6
4
4681217222735425362738477896240557087715867719310511701290000000
       Intangible Assets 
0
0
0
3,033
0
4,138
4,370
216
0
6,974
7,873
8,727
9,388
10,157
11,219
11,584
11,872
12,216
12,158
12,087
11,798
12,304
13,246
12,789
12,151
11,426
10,796
10,223
9,426
8,764
8,066
7,947
7,449
6,982
6,498
6,000
6,0006,4986,9827,4497,9478,0668,7649,42610,22310,79611,42612,15112,78913,24612,30411,79812,08712,15812,21611,87211,58411,21910,1579,3888,7277,8736,97402164,3704,13803,033000
       Long-term Assets Other 
-12
0
0
13
0
13
13
4,322
612
1,746
2,429
3,441
5,053
0
0
0
0
0
0
0
0
12,304
13,246
12,789
150
196
-10,849
-10,265
422
-8,791
-8,088
-7,964
210
214
6,498
0
06,498214210-7,964-8,088-8,791422-10,265-10,84919615012,78913,24612,304000000005,0533,4412,4291,7466124,322131301300-12
> Total Liabilities 
0
0
0
5,784
0
3,930
1,990
2,244
2,402
1,780
5,939
1,793
2,313
1,906
2,812
7,262
7,760
10,673
7,378
7,232
6,755
1,291
3,783
1,739
1,893
1,519
5,977
11,072
7,709
8,300
9,363
10,185
3,838
8,323
11,841
5,786
5,78611,8418,3233,83810,1859,3638,3007,70911,0725,9771,5191,8931,7393,7831,2916,7557,2327,37810,6737,7607,2622,8121,9062,3131,7935,9391,7802,4022,2441,9903,93005,784000
   > Total Current Liabilities 
0
0
0
5,034
0
3,180
1,266
1,717
1,916
1,373
5,571
1,464
2,024
1,498
2,444
1,933
7,629
1,410
4,273
4,140
6,702
1,120
3,652
1,647
1,893
1,506
2,977
11,072
7,709
8,300
9,362
10,185
3,838
8,323
11,841
5,786
5,78611,8418,3233,83810,1859,3628,3007,70911,0722,9771,5061,8931,6473,6521,1206,7024,1404,2731,4107,6291,9332,4441,4982,0241,4645,5711,3731,9161,7171,2663,18005,034000
       Short-term Debt 
0
0
0
4,647
0
0
0
158
0
158
3,202
158
158
0
0
0
5,158
0
0
0
2,658
158
131
92
53
13
3,000
0
0
0
0
0
0
0
0
0
0000000003,0001353921311582,6580005,1580001581583,20215801580004,647000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,658
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000002,65800000000000000000000
       Accounts payable 
0
0
0
236
0
2,625
618
708
880
600
158
471
1,207
0
0
0
1,671
0
0
0
452
1,120
0
0
1,009
1,506
2,977
11,072
1,820
8,300
9,362
10,185
3,838
0
0
0
0003,83810,1859,3628,3001,82011,0722,9771,5061,009001,1204520001,6710001,2074711586008807086182,6250236000
       Other Current Liabilities 
0
0
0
4,647
0
556
648
852
1,035
190
220
229
213
1,498
2,444
1,933
54
1,410
4,273
4,140
3,144
1,120
3,521
1,555
310
1,506
2,977
11,072
5,889
8,300
9,362
10,185
-3,838
8,323
11,841
5,786
5,78611,8418,323-3,83810,1859,3628,3005,88911,0722,9771,5063101,5553,5211,1203,1444,1404,2731,410541,9332,4441,4982132292201901,03585264855604,647000
   > Long-term Liabilities 
0
0
0
750
0
750
724
526
487
408
368
329
289
408
368
5,329
131
9,263
3,105
3,092
53
171
131
92
53
13
3,000
0
1,820
0
1
0
0
0
0
0
00000101,82003,000135392131171533,0923,1059,2631315,3293684082893293684084875267247500750000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,092
53
171
131
92
53
13
3,000
0
0
0
0
0
0
0
0
0
0000000003,000135392131171533,0920000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
000001000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,629
0
0
0
10,391
0
0
0
0
0
0
0
0
0
0
0
0000000000010,39100010,62900000000000000000000
> Total Stockholder Equity
46
0
0
869
0
19,724
17,200
14,583
12,240
8,992
22,500
21,591
20,495
18,945
17,063
14,353
9,729
6,181
15,213
12,187
9,236
19,967
16,097
29,451
23,917
19,105
13,225
7,574
13,992
10,847
11,127
6,894
11,031
7,887
3,387
8,965
8,9653,3877,88711,0316,89411,12710,84713,9927,57413,22519,10523,91729,45116,09719,9679,23612,18715,2136,1819,72914,35317,06318,94520,49521,59122,5008,99212,24014,58317,20019,72408690046
   Common Stock
0
0
0
100
0
639
639
639
639
639
1,278
1,278
1,278
18,945
17,063
14,353
1,703
6,181
15,213
12,187
3,023
19,967
16,097
29,451
4,815
19,105
13,225
7,574
6,007
10,847
11,127
6,894
8,969
7,887
3,387
0
03,3877,8878,9696,89411,12710,8476,0077,57413,22519,1054,81529,45116,09719,9673,02312,18715,2136,1811,70314,35317,06318,9451,2781,2781,2786396396396396390100000
   Retained Earnings Total Equity000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
46
0
0
0
0
0
0
-23,298
0
0
0
0
0
0
0
0
0
0
0
0
-35,817
0
0
0
-47,425
0
0
0
-87,649
0
0
0
-87,898
0
0
0
000-87,898000-87,649000-47,425000-35,817000000000000-23,29800000046
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,634
0
0
0
0
0
0
0
000000095,6340000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
1,133
1,364
23,298
2,469
4,504
5,512
6,305
44,755
18,945
17,063
14,353
8,026
6,181
15,213
12,187
17,877
19,967
16,097
29,451
36,845
19,105
-13,225
-7,574
101,641
-10,847
-11,127
-6,894
23,153
0
0
8,965
8,9650023,153-6,894-11,127-10,847101,641-7,574-13,22519,10536,84529,45116,09719,96717,87712,18715,2136,1818,02614,35317,06318,94544,7556,3055,5124,5042,46923,2981,3641,13300000



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue2,822
Cost of Revenue-22,961
Gross Profit-20,139-20,139
 
Operating Income (+$)
Gross Profit-20,139
Operating Expense-21,895
Operating Income-20,139-42,034
 
Operating Expense (+$)
Research Development2,571
Selling General Administrative0
Selling And Marketing Expenses0
Operating Expense21,8952,571
 
Net Interest Income (+$)
Interest Income549
Interest Expense-1,403
Other Finance Cost-711
Net Interest Income-1,565
 
Pretax Income (+$)
Operating Income-20,139
Net Interest Income-1,565
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-21,091-19,187
EBIT - interestExpense = -18,971
-18,579
-19,688
Interest Expense1,403
Earnings Before Interest and Taxes (EBIT)-17,568-19,688
Earnings Before Interest and Taxes (EBITDA)-17,459
 
After tax Income (+$)
Income Before Tax-21,091
Tax Provision-0
Net Income From Continuing Ops-22,440-21,091
Net Income-21,091
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses22,961
Total Other Income/Expenses Net-9521,565
 

Technical Analysis of Chemotech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Chemotech. The general trend of Chemotech is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Chemotech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Scandinavian ChemoTech AB Series B.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.99 < 2.14 < 2.48.

The bearish price targets are: 1.64 > 1.6350173651308.

Tweet this
Scandinavian ChemoTech AB Series B Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Scandinavian ChemoTech AB Series B. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Scandinavian ChemoTech AB Series B Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Scandinavian ChemoTech AB Series B. The current macd is -0.06424439.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Chemotech price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Chemotech. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Chemotech price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Scandinavian ChemoTech AB Series B Daily Moving Average Convergence/Divergence (MACD) ChartScandinavian ChemoTech AB Series B Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Scandinavian ChemoTech AB Series B. The current adx is 17.65.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Chemotech shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Scandinavian ChemoTech AB Series B Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Scandinavian ChemoTech AB Series B. The current sar is 1.6.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Scandinavian ChemoTech AB Series B Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Scandinavian ChemoTech AB Series B. The current rsi is 41.98. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Scandinavian ChemoTech AB Series B Daily Relative Strength Index (RSI) ChartScandinavian ChemoTech AB Series B Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Scandinavian ChemoTech AB Series B. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Chemotech price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Scandinavian ChemoTech AB Series B Daily Stochastic Oscillator ChartScandinavian ChemoTech AB Series B Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Scandinavian ChemoTech AB Series B. The current cci is -40.31677466.

Scandinavian ChemoTech AB Series B Daily Commodity Channel Index (CCI) ChartScandinavian ChemoTech AB Series B Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Scandinavian ChemoTech AB Series B. The current cmo is -14.97635972.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Scandinavian ChemoTech AB Series B Daily Chande Momentum Oscillator (CMO) ChartScandinavian ChemoTech AB Series B Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Scandinavian ChemoTech AB Series B. The current willr is -61.53846154.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Chemotech is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Scandinavian ChemoTech AB Series B Daily Williams %R ChartScandinavian ChemoTech AB Series B Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Scandinavian ChemoTech AB Series B.

Scandinavian ChemoTech AB Series B Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Scandinavian ChemoTech AB Series B. The current atr is 0.14256321.

Scandinavian ChemoTech AB Series B Daily Average True Range (ATR) ChartScandinavian ChemoTech AB Series B Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Scandinavian ChemoTech AB Series B. The current obv is -81,262.

Scandinavian ChemoTech AB Series B Daily On-Balance Volume (OBV) ChartScandinavian ChemoTech AB Series B Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Scandinavian ChemoTech AB Series B. The current mfi is 35.17.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Scandinavian ChemoTech AB Series B Daily Money Flow Index (MFI) ChartScandinavian ChemoTech AB Series B Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Scandinavian ChemoTech AB Series B.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-09STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-08-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-16CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-09-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-10STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-24STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-03CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-11-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-11WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside

6.3. Candlestick Patterns

Scandinavian ChemoTech AB Series B Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Scandinavian ChemoTech AB Series B based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.979
Ma 20Greater thanMa 501.813
Ma 50Greater thanMa 1001.978
Ma 100Greater thanMa 2001.994
OpenGreater thanClose1.730
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Chemotech with someone you think should read this too:
  • Are you bullish or bearish on Chemotech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Chemotech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Scandinavian ChemoTech AB Series B

I send you an email if I find something interesting about Scandinavian ChemoTech AB Series B.


Comments

How you think about this?

Leave a comment

Stay informed about Scandinavian ChemoTech AB Series B.

Receive notifications about Scandinavian ChemoTech AB Series B in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.